The global pharmaceutical sector is entering a pivotal phase. Although the FDA Modernization Act 2.0 has opened the door for Non-Animal Models (NAMs), widespread adoption is still slowed by major scalability challenges. This webinar will explore how advances in high-throughput stimulation, automated data capture, and standardized 3D human tissue models are delivering the consistency, predictive accuracy, and industrial-scale capacity necessary to advance NAMs from experimental research into regulatory practice.
For many years, scientists have had to choose between the limited scalability of sophisticated 3D tissue systems and the less reliable results produced by simplified 2D cell cultures. Even though specialized organ-on-a-chip technologies have demonstrated potential, they frequently fall short in terms of reproducibility and throughput for critical applications in toxicology and safety pharmacology. To address these limitations, the featured presenter will outline an integrated ecosystem strategy that combines ready-to-use cellular assays with automated instrumentation and advanced quantitative analytics.
The webinar will highlight practical applications across cardiac, skeletal muscle, and neuromuscular research. Particular attention will be given to the use of automated fluorescence and force measurements, together with precise optogenetic stimulation, to create highly accurate 3D disease models for Duchenne muscular dystrophy as well as advanced neuromuscular systems for evaluating neurotoxin potency.
Attendees will also receive an exclusive preview of next-generation 96-well functional platforms. These emerging technologies are engineered to expand electrophysiology and contractile force testing at scale while maintaining strong data quality, representing a major leap forward in data richness and statistical reliability.
Click here to register for this webinar to learn how laboratories can scale 3D human-functional odels to drive more predictive drug discovery benefits in the new era of drug discovery.
For many years, scientists have had to choose between the limited scalability of sophisticated 3D tissue systems and the less reliable results produced by simplified 2D cell cultures. Even though specialized organ-on-a-chip technologies have demonstrated potential, they frequently fall short in terms of reproducibility and throughput for critical applications in toxicology and safety pharmacology. To address these limitations, the featured presenter will outline an integrated ecosystem strategy that combines ready-to-use cellular assays with automated instrumentation and advanced quantitative analytics.
The webinar will highlight practical applications across cardiac, skeletal muscle, and neuromuscular research. Particular attention will be given to the use of automated fluorescence and force measurements, together with precise optogenetic stimulation, to create highly accurate 3D disease models for Duchenne muscular dystrophy as well as advanced neuromuscular systems for evaluating neurotoxin potency.
Attendees will also receive an exclusive preview of next-generation 96-well functional platforms. These emerging technologies are engineered to expand electrophysiology and contractile force testing at scale while maintaining strong data quality, representing a major leap forward in data richness and statistical reliability.
Click here to register for this webinar to learn how laboratories can scale 3D human-functional odels to drive more predictive drug discovery benefits in the new era of drug discovery.